⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15993807 | 0.79 | — | — | |
| SCHEMBL10625576 | 0.77 | PGK1 (0.32) | — | |
| SCHEMBL21026756 | 0.77 | — | — | |
| SCHEMBL15994015 | 0.76 | — | — | |
| SCHEMBL26004726 | 0.75 | MMP8 (0.36) | — | |
| SCHEMBL6006214 | 0.75 | CES2 (0.38) | — | |
| Alcohol SCHEMBL8434419 | 0.74 | CA2 (0.43) | — | |
| SCHEMBL9700996 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL312534 | 0.71 | — | — | |
| SCHEMBL12605727 | 0.70 | GLS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656240-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4436662-B1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250214989-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| EP-4436662-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084442-B2 | Naphthyridinone derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| CN-118382623-A | Naphthyridinone derivatives for use in the treatment of diseases or disorders | 诺华股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230203032-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| WO-2023094965-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-06-01 | — | — | WO | disclosed |
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |